Kyverna Therapeutics shareholders elect two Class I directors and ratify BDO as auditor at 2025 Annual Meeting

Kyverna Therapeutics, Inc.

30,546,469 shares (70.67% of outstanding) represented at May 29, 2025 Annual Meeting.
Beth Seidenberg, M.D. elected with 18,161,970 votes for, 2,508,848 withheld.
Fred E. Cohen, M.D., D. Phil. elected with 18,513,181 votes for, 2,157,637 withheld.
Ratification of BDO USA, P.C. as auditor for 2025 passed with 30,374,716 for, 142,212 against, 29,541 abstain.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.